Paratek Pharmaceuticals Overview

  • Year Founded
  • 1996

Year Founded

  • Status
  • Public

  • Employees
  • 275

Employees

  • Investments
  • 1

  • Share Price
  • $2.23
  • (As of Wednesday Closing)

Paratek Pharmaceuticals General Information

Description

Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.

Contact Information

Ownership Status
Publicly Held
Financing Status
Private Equity-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Former Stock Listing
PRTK
Corporate Office
  • 1000 First Avenue
  • Suite 200
  • King of Prussia, PA 19406
  • United States
+1 (617) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Paratek Pharmaceuticals Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.23 $2.19 $1.29 - $3.65 $128M 57.3M 659K -$1.11

Paratek Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 30-Jun-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 340,638 305,972 369,009 388,211
Revenue 167,617 150,788 120,951 43,517
EBITDA (44,385) (45,942) (40,742) (77,238)
Net Income (62,732) (63,566) (59,084) (96,541)
Total Assets 145,792 172,538 183,869 176,853
Total Debt 259,756 258,414 255,736 252,018
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Paratek Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Paratek Pharmaceuticals‘s full profile, request access.

Request a free trial

Paratek Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on te
Pharmaceuticals
King of Prussia, PA
275 As of 2023
00000
00000 0000-00-00
000000000000 00000

000000

quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequ
0000000000000
Camberwell, Australia
00 As of 0000
000.00
000000000 000.00

000000

tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, qu
0000000000000
Melbourne, Australia
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Paratek Pharmaceuticals Competitors (76)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Neuren Pharmaceuticals Corporation Camberwell, Australia 00 000.00 000000000 000.00
Mesoblast Corporation Melbourne, Australia 00 00000 000000000 00000
Ionis Pharmaceuticals Corporate Backed or Acquired Carlsbad, CA 000 0000 00000000000 0000
Amyndas Pharmaceuticals Corporation Bala Cynwyd, PA 0000000000
Scynexis Formerly VC-backed Jersey City, NJ 00 00000 00000000 00000
You’re viewing 5 of 76 competitors. Get the full list »

Paratek Pharmaceuticals Patents

Paratek Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021288202-A1 Crystalline forms of omadacycline, methods of synthesis thereof and methods of use thereof Pending 11-Jun-2020 0000000000
CA-3179596-A1 Crystalline forms of omadacycline, methods of synthesis thereof and methods of use thereof Pending 11-Jun-2020 0000000000
EP-4165016-A1 Crystalline forms of omadacycline, methods of synthesis thereof and methods of use thereof Pending 11-Jun-2020 0000000000
US-20230357135-A1 Crystalline forms of omadacycline, methods of synthesis thereof and methods of use thereof Pending 11-Jun-2020 0000000000
US-20210346408-A1 Methods of treating mycobacterial infections using tetracycline compounds Pending 04-Sep-2018 A61K31/65 0
To view Paratek Pharmaceuticals’s complete patent history, request access »

Paratek Pharmaceuticals Executive Team (26)

Name Title Board Seat Contact Info
Sarah Higgins Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Chris Bostrom Chief Financial Officer
Jonathan Light General Counsel, Corporate Secretary and Chief Compliance Officer
Karen McGrath Chief People Officer & Senior Vice President, Human Resources
Katie Zitoli Senior Director, Finance and Controller
You’re viewing 5 of 26 executive team members. Get the full list »

Paratek Pharmaceuticals Board Members (11)

Name Representing Role Since
0000 00000000 Paratek Pharmaceuticals Board Member 000 0000
00000000 00000000 Paratek Pharmaceuticals Board Member 000 0000
0000 00000000 Paratek Pharmaceuticals Board Member 000 0000
You’re viewing 3 of 11 board members. Get the full list »

Paratek Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Paratek Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Paratek Pharmaceuticals‘s full profile, request access.

Request a free trial

Paratek Pharmaceuticals Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Transcept Pharmaceuticals 30-Oct-2014 0000000000 000.00 Pharmaceuticals
To view Paratek Pharmaceuticals’s complete acquisitions history, request access »

Paratek Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated April, 01, 2022

42.83 | Severe Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 14,912

Rank

00.0

Percentile

Pharmaceuticals

Industry

00 of 965

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 455

Rank

00.00

Percentile

To view Paratek Pharmaceuticals’s complete esg history, request access »

Paratek Pharmaceuticals FAQs

  • When was Paratek Pharmaceuticals founded?

    Paratek Pharmaceuticals was founded in 1996.

  • Who is the founder of Paratek Pharmaceuticals?

    Stuart Levy MD and Walter Gilbert Ph.D are the founders of Paratek Pharmaceuticals.

  • Where is Paratek Pharmaceuticals headquartered?

    Paratek Pharmaceuticals is headquartered in King of Prussia, PA.

  • What is the size of Paratek Pharmaceuticals?

    Paratek Pharmaceuticals has 275 total employees.

  • What industry is Paratek Pharmaceuticals in?

    Paratek Pharmaceuticals’s primary industry is Pharmaceuticals.

  • Is Paratek Pharmaceuticals a private or public company?

    Paratek Pharmaceuticals is a Public company.

  • What is the current stock price of Paratek Pharmaceuticals?

    As of 20-Sep-2023 the stock price of Paratek Pharmaceuticals is $2.23.

  • What is the current market cap of Paratek Pharmaceuticals?

    The current market capitalization of Paratek Pharmaceuticals is $128M.

  • What is Paratek Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Paratek Pharmaceuticals is $168M.

  • Who are Paratek Pharmaceuticals’s competitors?

    Neuren Pharmaceuticals, Mesoblast, Ionis Pharmaceuticals, Amyndas Pharmaceuticals, and Scynexis are some of the 76 competitors of Paratek Pharmaceuticals.

  • What is Paratek Pharmaceuticals’s annual earnings per share (EPS)?

    Paratek Pharmaceuticals’s EPS for 12 months was -$1.11.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »